TABLE 3.

Correlation of antimicrobial susceptibility profiles with Nocardia species designation

Drug pattern typea	Nocardia sp.	No. of strains	Antimicrobial susceptibility profileb
			Nonsusceptible (% intermediate or resistant)	Susceptible (%)
Ia	N. abscessus complexc	9	Imipenem (78), ciprofloxacin (89), moxifloxacin (89), and clarithromycin (89)	Amoxicillin-clavulanic acid, ceftriaxone, cefepime, tobramycin, amikacin, doxycycline (89), linezolid, and SXT
Iad	N. arthritidis/N. gamkensis/N. exalbida species cluster,e N. asiatica	13	Same as type I but nonsusceptible to amoxicillin-clavulanic acid (69)	Same as type I except nonsusceptible to amoxicillin-clavulanic acid
IIIa	N. nova complexf	28	Amoxicillin-clavulanic acid (74), tobramycin, doxycycline (89), ciprofloxacin, and moxifloxacin	Ceftriaxone (85), cefepime (74), imipenem, amikacin, clarithromycin, linezolid, and SXT
IVa	N. transvalensis complexg	5	Imipenem, tobramycin, amikacin (80), doxycycline (80), and clarithromycin (80)	Ceftriaxone, ciprofloxacin, moxifloxacin (80), linezolid, and SXT (80)
Va	N. farcinica	36	Ceftriaxone, cefepime, tobramycin, doxycycline (83), and clarithromycin	Amoxicillin-clavulanic acid (78), amikacin, moxifloxacin(80), linezolid, and SXT; variable susceptibility toward imipenem (53) and ciprofloxacin (50)
VIa	N. cyriacigeorgica	20	Amoxicillin-clavulanic acid (80 [intermediate resistance]), ciprofloxacin, moxifloxacin, and clarithromycin (75)	Ceftriaxone, imipenem, tobramycin, amikacin, doxycycline (50), linezolid, and SXT
VIIh	N. otitidiscaviarum	6	Amoxicillin-clavulanic acid, ceftriaxone, cefepime, imipenem, doxycycline (83), ciprofloxacin, moxifloxacin (83), and clarithromycin	Amikacin, linezolid, and SXT
VIIIh	N. brasiliensis	6	Cefepime, imipenem (83), doxycycline (83), ciprofloxacin, and clarithromycin	Amoxicillin-clavulanic acid, tobramycin, amikacin, linezolid, and SXT
IXd	N. asteroides sensu stricto, N. pneumoniae, N. amamiensis, N. beijingensis, N. thailandica, N. vinacea, N. anaemiae	15	Amoxicillin-clavulanic acid and ciprofloxacin (87)	Ceftriaxone, cefepime, imipenem (80), tobramycin, amikacin, doxycycline (67), clarithromycin, linezolid, and SXT

^aDescribed by Wallace et al. (2) and/or Brown-Elliott et al. (1).

^bIf no value is indicated, the percent susceptible or nonsusceptible is ≥90%.

^cN. abscessus complex: contains strains of N. abscessus and the N. abscessus/N. arthritidis-like species cluster, which lacks a type strain but contains isolates similar to N. abscessus and N. arthritidis (5).

^dNew drug pattern type described in this study.

^eN. arthritidis/N. gamkensis/N. exalbida species cluster: this cluster contains strains similar to the three type strains N. arthritidis DSM 44731^T, N. gamkensis DSM 44956^T, and N. exalbida DSM 44883^T (5).

^fN. nova complex: contains strains of N. nova, N. africana, N. cerradoensis, N. kruczakiae, N. veterana, and the N. nova/cerradoensis/kruczakiae/aobensis-like species cluster, which lacks a type strain but contains isolates similar to N. nova, N. cerradoensis, N. kruczakiae, and N. aobensis (5).

^gN. transvalensis complex: contains strains of N. transvalensis and N. wallacei.

^hConsistent with the drug pattern type described by Brown-Elliott et al. (1) and assigned a number in this study.